Bellerophon: Last patient enrolled in INOpulse study for treatment of fILD

Bellerophon Therapeutics announced that the last patient has been enrolled in the ongoing Phase 3 REBUILD study of INOpulse , a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease,fILD . The Company now expects to report pivotal top-line results in mid- 2023."We are pleased to have completed enrollment in this important study sooner than previously anticipated, which represents a significant milestone for Bellerophon, our INOpulse clinical development program, and the fILD patient community. Based on the earlier than expected enrollment completion, we now expect to report top-line results from REBUILD in mid-2023," said Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors.